Educational Overview
Ipamorelin vs. Tesamorelin: What the Research Shows
Originally published 3/29/2024 · Updated 10/6/2026
Ipamorelin and tesamorelin are often mentioned together because both relate to growth hormone signaling. They are different molecules, studied in different ways, and with very different regulatory standing. This article explains how they differ, what clinical research has examined, and what remains unknown.
Educational Overview
IPAMORELIN VS TESAMORELIN
Ipamorelin
Tesamorelin
Type: Synthetic peptide that acts on the ghrelin receptor
Type: Synthetic analogue of growth hormone–releasing hormone
Studied for: Post-surgical bowel function (phase 2 trial; primary endpoint not met)
Studied for: Abdominal (visceral) fat in adults with HIV-associated lipodystrophy
FDA status: Not FDA-approved for any use
FDA status: Brand-name drug approved only for HIV lipodystrophy; not for weight loss
Images are for illustration purposes only.
Important
- Ipamorelin is not FDA-approved for any use.
- Tesamorelin is the active ingredient in an FDA-approved brand-name drug, indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated for general weight loss[3].
- Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
- Nothing here is medical advice, a recommendation, or a promise of results. See our FDA Peptide Review for the regulatory outlook on peptides.
At a Glance
|
Ipamorelin |
Tesamorelin |
| What it is |
A synthetic peptide that mimics ghrelin, acting on the ghrelin receptor[2] |
A synthetic analogue of growth hormone–releasing hormone[1] |
| Clinical research |
A phase 2 trial in 117 bowel-surgery patients did not meet its primary endpoint[2] |
Phase III trials in adults with HIV and abdominal fat accumulation[1] |
| FDA status |
Not FDA-approved for any use |
Brand-name drug approved for HIV lipodystrophy only; not for weight loss[3] |
Explore the Topic
Open any section below to learn more.
What is ipamorelin?
▼
Ipamorelin is a synthetic peptide classed as a ghrelin mimetic, meaning it acts on the ghrelin receptor, the same receptor targeted by the natural hormone ghrelin[2]. Ghrelin-receptor agonists are of research interest partly because stimulating this receptor can influence growth hormone release.
Ipamorelin has not been approved by the FDA. Its published human clinical research is limited, and the best-known controlled trial studied post-surgical bowel function, not body composition[2].
What is tesamorelin?
▼
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH)[1]. It is the active ingredient in an FDA-approved brand-name drug indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy[3].
That approval is specific. The prescribing information notes limitations of use: the drug is not intended for general weight loss management[3].
How do they differ?
▼
Both are connected to growth hormone signaling, but through different receptors. Ipamorelin acts on the ghrelin receptor[2]. Tesamorelin is modeled on GHRH, the hormone that signals the pituitary gland through its own receptor[1].
More important than the mechanism is the evidence. Tesamorelin has randomized, controlled phase III data in a defined patient group. Ipamorelin does not have comparable data for body composition, and the two have not been compared head to head in a clinical trial that we are aware of.
What has been studied in people?
▼
Tesamorelin: In an analysis of 806 adults with HIV and abdominal obesity from phase III trials, participants whose visceral adipose tissue fell by at least 8% after 26 weeks of tesamorelin also had greater reductions in the liver enzymes ALT and AST than non-responders[1]. This was a secondary analysis in a specific population.
Ipamorelin: A multicenter, double-blind, placebo-controlled phase 2 trial enrolled 117 patients after bowel resection. Median time to tolerating solid food was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that was not statistically significant (p=0.15). The primary endpoint was not met, and adverse event rates were similar between groups[2].
What the evidence can — and can’t — tell us
▼
| What has been found |
What is still unknown |
| Tesamorelin is studied and FDA-approved for abdominal fat in HIV lipodystrophy[1][3]. |
Whether results apply to people without HIV lipodystrophy. The label says it is not for weight loss, and it lacks long-term cardiovascular safety data[3]. |
| Ipamorelin was well tolerated in one phase 2 trial[2]. |
That trial did not meet its primary endpoint, and it did not study body composition, muscle, or long-term use[2]. |
| Each has a distinct mechanism. |
How they compare directly, or whether one is “better” than the other. We are not aware of head-to-head clinical trials. |
Regulatory status
▼
Ipamorelin is not FDA-approved. Tesamorelin is the active ingredient in an FDA-approved brand-name product with a narrow indication, as described above[3]. An FDA-approved drug and a compounded preparation are not the same thing: compounded drugs are made by licensed pharmacies for individual patients and have not been evaluated by the FDA for safety, effectiveness, or quality.
Regulatory decisions about peptides can change. We track developments in our FDA Peptide Review.
Safety Considerations
▼
- Tesamorelin contraindications: the prescribing information lists disruption of the hypothalamic-pituitary axis (for example from pituitary surgery, tumor, head trauma, or irradiation), active malignancy, pregnancy, and known hypersensitivity to tesamorelin or mannitol[3].
- Other tesamorelin cautions in its prescribing information include elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity reactions, and injection-site reactions. Ask your clinician to review the current label.
- Ipamorelin: in the one phase 2 trial, adverse event rates were similar to placebo[2]. Long-term safety and safety in otherwise healthy adults have not been established.
- “Research Use Only” and unlicensed sources carry risks of wrong contents, wrong dose, contamination, or no sterility testing.
- Injectable products can cause injection-site reactions and, rarely, severe allergic reactions. Seek emergency care for hives, wheezing, difficulty breathing, or swelling of the face, lips, tongue, or throat.
- Athletes: growth hormone–related substances may be prohibited by anti-doping rules. Check the current WADA list.
Our Perspective
This section is editorial. Comparison articles can make two molecules sound interchangeable. The research shows they are not. If you come across either one from any source, we suggest asking three questions:
- Which exact molecule is it, and who prepared it?
- What is its regulatory status for the intended use?
- What does the evidence show in people like me? Ask which study supports it and who was in it.
Have questions about peptide therapy?
Talk with our clinical team about your questions, in person or via telemedicine.
Call (561) 214-3323
Referenced Research
1
In 806 adults with HIV and abdominal obesity enrolled in phase III trials of tesamorelin, a growth hormone–releasing hormone analogue, 64% had elevated baseline liver enzymes. After 26 weeks, those whose visceral fat fell by at least 8% had greater reductions in ALT (−8.9 U/L) and AST (−3.8 U/L) than non-responders, independent of viral hepatitis status. This was a secondary analysis in a specific population.
Fourman LT, Czerwonka N, Feldpausch MN, et al. “Visceral Fat Reduction with Tesamorelin Is Associated with Improved Liver Enzymes in HIV.” AIDS, 2017;31(16):2253–2259. doi:10.1097/QAD.0000000000001614.
2
A multicenter, double-blind, placebo-controlled phase 2 trial tested the ghrelin mimetic ipamorelin in 117 patients after bowel resection (114 analyzed). Median time to tolerating solid food was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15). The primary endpoint was not met, no significant efficacy differences were found, and the drug was well tolerated with similar adverse event rates.
Beck DE, Sweeney WB, McCarter MD. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International Journal of Colorectal Disease, 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8.
3
A clinical policy summarizing the prescribing information for tesamorelin (Egrifta SV) states that it is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Limitations of use include that it is not intended for general weight loss management and that long-term cardiovascular safety data are lacking. Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, pregnancy, and hypersensitivity to tesamorelin or mannitol.
Clinical Policy: Tesamorelin (Egrifta SV), summarizing FDA-approved prescribing information. Meridian Health Plan. View document
Important Disclosures
- This article is for educational purposes only and is not medical advice. These statements have not been evaluated by the U.S. Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease.
- Ipamorelin is not FDA-approved. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
- Images are for illustration purposes only. Individual results vary.
- Treatment decisions are made solely by an independent, licensed clinician after an individualized evaluation, and a doctor-patient relationship is established only after a qualifying consultation.
Tagged differences between ipamorelin & tesamorelin, ipamorelin fatigue, ipamorelin growth hormone, ipamorelin vs. tesamorelin, ipamorelin water retention, peptide education, side effects of tesamorelin, tesamorelin growth hormone peptide, tesamorelin side effects, tesamorelin water retention, West Palm Beach peptide therapy
